A new University of Michigan study has revealed that the excessive of testing of type 2 diabetes patients can be linked to over treatment.
The research by American researchers revealed that over treatment can lead to harming the patient, create inefficiency and waste in the healthcare system.
They recommended that patients and doctors should question the value of routine tests.
Professional societies and regulatory bodies recommend that glycated haemoglobin testing is performed once or twice a year on patients with good blood sugar control and no history of hypoglycaemia.
Nevertheless, the authors opined that the association between repeat tests and potential over treatment is concerning, particularly because of the link between intensive treatment and adverse health outcomes. These include hypoglycemia, cardiovascular problems, and death.
Lead researcher Rodney A Hayward of the University of Michigan said improvements in diabetes care are a medical success story, but increasing evidence suggests that overtly aggressive treatment is an under-appreciated problem.
The results have showed that over 60 percent of patients received many more tests than the current recommendations of one to two tests per year. In total, 54.5 percent had three to four tests over one year, and 5.8 percent of patients had five or more tests over one year.
Rodney added that this latest study probably greatly underestimates the size of the over treatment problem because current guidelines have not changed since these were developed 25 years ago when diabetes complications were more common.
The study is published in Journal BMJ.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
